Boulevard Bio emerged from stealth with about $65 million in launch financing to reimagine autoimmune treatment through B cell biology. The New York-based company, backed entirely by Deerfield Management and its Discovery and Development platform, introduced a quarterly-dosing antibody program centered on BAFF and APRIL targeting. Its lead candidate, BLVD101, is being evaluated initially in IgA nephropathy, a progressive kidney disease that contributes to end-stage renal disease risk. Interim Phase I data from healthy volunteers were described as supporting the possibility of dosing once every 12 weeks, aiming to reduce treatment burden for chronic patients. The company also outlined a multi-specific antibody pipeline intended to deliver more durable disease control with less frequent schedules. For biotech investors and clinical teams, Boulevard’s launch emphasizes a shift toward frequency-optimized biologics in autoimmune nephrology, with immunology rationale anchored in cytokine biology that drives B cell survival and activation.